---
document_datetime: 2026-01-19 12:39:14
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imuldosa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imuldosa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7527574
conversion_datetime: 2026-01-20 20:38:27.242626
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMULDOSA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 19/12/2025                          | 15/01/2026                                  | SmPC and PL                      | To extend the indication to include treatment of |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313404                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To extend the indication to include treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy or have medical contraindications to such therapies. The change follows the approval of the same change for the reference product Stelara. Consequently, Sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package   |            |     | moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy or have medical contraindications to such therapies. The change follows the approval of the same change for the reference product Stelara. Consequently, Sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet is updated accordingly.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000306938 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/12/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000280923   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                    | 04/09/2025   | N/A        |             |                                                                                                 |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000276498   | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted | 04/09/2025   | N/A        |             |                                                                                                 |
| Variation type IB / EMA/VR/0000272232   | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                     | 23/06/2025   | 15/01/2026 | SmPC        |                                                                                                 |
| Variation type IB / EMA/VR/0000274978   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet                                                                                                                                                                                                                                                     | 05/06/2025   | 15/01/2026 | SmPC and PL | To update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information |

<div style=\"page-break-after: always\"></div>

of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted

C.I.2.a - To update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003 (a phase 1, openlabel, drug interaction study to evaluate the effect of ustekinumab on cytochrome P450 enzyme activities following induction and maintenance dosing in participants with active Crohn's disease or ulcerative colitis) and to update sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001 (a phase 3, randomised, double-blind, placebocontrolled, parallel-group, multicentre protocol to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis). The PL is updated accordingly. The change follows assessment of the same change for the reference product Stelara.   Additionally, the MAH took the opportunity to update the wording of the polysorbate warning in Section 2 of the PL, in line with the EC excipient guideline, and to implement minor based on results from study CNTO1275CRD1003 and to update sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001. The PL is updated accordingly. The change follows assessment of the same change for the reference product Stelara. Additionally, the MAH took the opportunity to update the wording of the polysorbate warning in Section 2 of the PL,

<div style=\"page-break-after: always\"></div>

|                                       | editorial changes throughout the PI to align with the QRD template.                                                                                                                                                     |            |            |      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| Variation type IB / EMA/VR/0000266943 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted | 03/06/2025 | 15/01/2026 | SmPC |